SL
EW icon

Salomon & Ludwin’s Edwards Lifesciences EW Stock Holding History

Salomon & Ludwin’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.5K Hold
142
– – ﹤0.01% 1454
2025
Q4 		$12K Sell
142
-42
-23% -$3.45K ﹤0.01% 1327
2025
Q3 		$14.2K Buy
+184
New +$14.4K ﹤0.01% 1046

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Salomon & Ludwin's EW Position: Q1 2026 in Review

Salomon & Ludwin held its Edwards Lifesciences (EW) position steady in Q1 2026 at 142 shares worth $11.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1454.

Salomon & Ludwin first reported a position in EW in Q3 2025 and has held it in 3 quarters since. The position peaked at $14.2K in Q3 2025. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Salomon & Ludwin held 142 shares of Edwards Lifesciences worth $11.5K as of Q1 2026.
  • Salomon & Ludwin left its Edwards Lifesciences share count unchanged in Q1 2026.
  • Edwards Lifesciences made up ﹤0.01% of Salomon & Ludwin's portfolio in Q1 2026, its #1454 holding.
  • Salomon & Ludwin first reported a position in Edwards Lifesciences in Q3 2025 and has held it in 3 quarters since.
  • Salomon & Ludwin's Edwards Lifesciences position peaked at $14.2K in Q3 2025.
  • 1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Salomon & Ludwin's 13F filing for Q1 2026, filed 11 May 2026.